Work

A Phase II Study of First-Line Sintilimab Combined With Anlotinib and Platinum-Based Chemotherapy in Unresectable MPM

Year: 2025

Type: article

Abstract: This single-arm, open-label, phase II trial enrolls treatment-naïve patients aged ≥18 years with histologically confirmed unresectable or advanced MPM (stage IIIB/IV), ECOG 0-1, and measurable lesions per mRECIST 1.1.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.16793063

Authors: Duan, Jianchun, Wu, Xinyu, Wan, Rui

Institution: Cancer Hospital of Chinese Academy of Medical Sciences

Language: English

Topic: Occupational and environmental lung diseases

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7078290627

FWCI:

Cites:

Cited by:

Related to: